Aim: Darigabat is an α2/3/5 subunit-selective positive allosteric modulator of GABAAreceptors that has demonstrated broad-spectrum activity in several preclinical models of epilepsy as well as in a clinical photoepilepsy trial.
Aim: Darigabat is an α2/3/5 subunit-selective positive allosteric modulator of GABAAreceptors that has demonstrated broad-spectrum activity in several preclinical models of epilepsy as well as in a clinical photoepilepsy trial.
You are now leaving cerevel.com, a website provided by Cerevel Therapeutics. The content displayed on external websites is not controlled by Cerevel, and Cerevel assumes no responsibility for the information or statements on external websites.